person · Reporting owner
Martin Christopher Nathan
Disclosed activity across 3 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ACHIEVE LIFE SCIENCES, INC.ACHV · Entity 5072 | Director | July 27, 2026 | July 29, 2026 |
| Edgewise Therapeutics, Inc.EWTX · Entity 3965 | Director | June 05, 2026 | June 16, 2026 |
| Oruka Therapeutics, Inc.ORKA · Entity 3781 | Director | June 02, 2026 | June 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ACHIEVE LIFE SCIENCES, INC.
Report date July 27, 2026 · Filed July 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.18 · Expires 2036-07-27 | Direct | 25,000 |
Reported balance
After 2026-07-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-27 · Grant · Acquired 25,000 · Balance 25,000 F1: The options vest 100% on the earlier of July 27, 2027 or the date immediately prior to the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's provision of service to the Issuer on the vesting date. |
| Restricted Stock Unit (RSU)SEC Table II · derivative / convertible security · Expires 2036-07-27 | Direct | 16,700 |
Reported balance
After 2026-07-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-27 · Grant · Acquired 16,700 · Balance 16,700 F2: Each RSU represents a contingent right to receive one share of the Issuer's common stock at settlement. F3: Pursuant to the terms of the RSU, the shares underlying the RSU vest 100% on the earlier of July 27, 2027 or the date immediately prior to the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's provision of service to the Issuer on the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest 100% on the earlier of July 27, 2027 or the date immediately prior to the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's provision of service to the Issuer on the vesting date.
F2: Each RSU represents a contingent right to receive one share of the Issuer's common stock at settlement.
F3: Pursuant to the terms of the RSU, the shares underlying the RSU vest 100% on the earlier of July 27, 2027 or the date immediately prior to the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's provision of service to the Issuer on the vesting date.
Edgewise Therapeutics, Inc.
Report date June 05, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.59 · Expires 2036-06-05 | Direct | 16,377 |
Reported balance
After 2026-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 16,377 · Balance 16,377 F1: 100% of the Stock Options granted on June 5, 2026 will become vested on the earlier of (i) June 5, 2027 or (ii) the business day prior to the 2027 annual meeting of stockholder. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the Stock Options granted on June 5, 2026 will become vested on the earlier of (i) June 5, 2027 or (ii) the business day prior to the 2027 annual meeting of stockholder.
Oruka Therapeutics, Inc.
Report date June 02, 2026 · Filed June 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $55.23 · Expires 2036-06-01 | Direct | 9,136 |
Reported balance
After 2026-06-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-02 · Grant · Acquired 9,136 · Balance 9,136 F1: The option vests as to 1/12 of the underlying shares monthly from June 2, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests as to 1/12 of the underlying shares monthly from June 2, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 27, 2026 Filed Jul 29, 2026 21:24 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | GrantRestricted Stock Unit (RSU) · Derivative | 16,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-324256 · ownership.xml · derivative · entry 2 Martin Christopher Nathan · CIK 0002097992 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,700 Underlying: Common Stock · 16,700 shares Expires 2036-07-27 F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock at settlement. F3 · derivative.exercise_date: Pursuant to the terms of the RSU, the shares underlying the RSU vest 100% on the earlier of July 27, 2027 or the date immediately prior to the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's provision of service to the Issuer on the vesting date. Read SEC document |
| July 27, 2026 Filed Jul 29, 2026 21:24 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $6.18 | $0.00 |
DisclosureSEC source: 0001193125-26-324256 · ownership.xml · derivative · entry 1 Martin Christopher Nathan · CIK 0002097992 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2036-07-27 F1 · derivative.exercise_date: The options vest 100% on the earlier of July 27, 2027 or the date immediately prior to the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's provision of service to the Issuer on the vesting date. Read SEC document |
| June 05, 2026 Filed Jun 16, 2026 22:16 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantStock Options (Right to buy) · Derivative | 16,377 | $0.00 Strike: $35.59 | $0.00 |
DisclosureSEC source: 0002097992-26-000001 · primarydocument.xml · derivative · entry 1 Martin Christopher Nathan · CIK 0002097992 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,377 Underlying: Common Stock · 16,377 shares Expires 2036-06-05 F1 · derivative.exercise_date: 100% of the Stock Options granted on June 5, 2026 will become vested on the earlier of (i) June 5, 2027 or (ii) the business day prior to the 2027 annual meeting of stockholder. Read SEC document |
| June 02, 2026 Filed Jun 3, 2026 20:49 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | GrantStock Option (right to buy) · Derivative | 9,136 | $0.00 Strike: $55.23 | $0.00 |
DisclosureSEC source: 0000907654-26-000050 · form4.xml · derivative · entry 1 Martin Christopher Nathan · CIK 0002097992 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,136 Underlying: Common Stock · 9,136 shares Expires 2036-06-01 F1 · derivative.exercise_date: The option vests as to 1/12 of the underlying shares monthly from June 2, 2026. Read SEC document |
| May 11, 2026 Filed May 13, 2026 20:35 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | GrantStock Option (right to buy) · Derivative | 47,250 | $0.00 Strike: $5.59 | $0.00 |
DisclosureSEC source: 0001193125-26-221774 · ownership.xml · derivative · entry 1 Martin Christopher Nathan · CIK 0002097992 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,250 Underlying: Common Stock · 47,250 shares Expires 2036-05-11 F1 · derivative.exercise_date: The option will vest in substantially equal monthly installments over 36 months commencing May 11, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| December 11, 2025 Filed Dec 11, 2025 21:41 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $30.21 | $0.00 |
DisclosureSEC source: 0000907654-25-000019 · form4.xml · derivative · entry 1 Martin Christopher Nathan · CIK 0002097992 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2035-12-10 F1 · derivative.exercise_date: The option vests as to 1/36 of the underlying shares monthly from December 11, 2025. Read SEC document |
| November 19, 2025 Filed Nov 25, 2025 00:08 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantStock Options (Right to buy) · Derivative | 45,150 | $0.00 Strike: $22.34 | $0.00 |
DisclosureSEC source: 0002097992-25-000005 · primarydocument.xml · derivative · entry 1 Martin Christopher Nathan · CIK 0002097992 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,150 Underlying: Common Stock · 45,150 shares Expires 2035-11-19 F1 · derivative.exercise_date: 1/36th of the shares subject to the option vest each month beginning on December 19, 2025, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.